DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: OCREVUS (ocrelizumab)
       *****************************************************
       #Post#: 4972--------------------------------------------------
       (ECTRIMS) Ocrelizumab may double serious infection risk in MS
       By: agate Date: October 26, 2025, 8:06 pm
       ---------------------------------------------------------
       From MedPage Today (September 28, 2025)--"Ocrelizumab may double
       serious infection risk in MS":
  HTML https://www.medpagetoday.com/meetingcoverage/ectrims/117680
       The abstract:
       [font=arial]Long-term safety risks among patients with multiple
       sclerosis treated with ocrelizumab: An observational
       study[/font]
       [font=arial]
       Alise K. Carlson1, Mengke Du1, Scott Husak1, Jeffrey Cohen1,
       Robert J. Fox1, Daniel Ontaneda1[/font]
       [font=arial]
       1Mellen Center for Multiple Sclerosis Treatment and Research,
       Neurological Institute, Cleveland Clinic, Cleveland, OH, United
       States[/font]
       Introduction:
       The use of B-cell depleting therapies for treatment of multiple
       sclerosis (MS) has been associated with good control of disease
       activity and prevention of long-term disability accrual but may
       also be associated with increased risk of serious infections.
       Objectives/Aims:
       To characterize the magnitude of this risk in a large real-world
       population.
       Methods:
       Retrospective data from the Mellen Center for Multiple Sclerosis
       Treatment and Research at the Cleveland Clinic were used to
       analyze the incidence of serious infections in MS patients
       treated with ocrelizumab compared to a propensity-matched cohort
       of patients treated with platform injectable therapies, to
       evaluate differences in time from treatment onset to first
       serious infection, and to examine the relationship between
       immunoglobulin levels and incidence of serious infections in
       patients treated with ocrelizumab. Incidence of serious
       infections between those treated with ocrelizumab aged <55,
       55-60, and >60 years was also assessed.
       Results:
       The risk for serious infection was higher in patients treated
       with ocrelizumab (n = 2,551) than for patients treated with
       platform injectable therapies (n = 1,307) in a
       propensity-matched cohort (OR 1.98 [1.52, 2.59], p = <0.001).
       The rate of serious infections per 100 person-years for the
       ocrelizumab and platform injectable therapies groups were 4.21
       and 2.64, respectively. Time to first serious infection was
       shorter in the ocrelizumab-treated cohort (HR 1.86 [95% CI 1.45,
       2.39]). Hypogammaglobulinemia was not associated with increased
       risk of serious infection(s) in ocrelizumab-treated patients
       (1.36 [95% CI 0.99, 1.89], p = 0.07 for IgG and 1.21 [95% CI
       0.90, 1.63], p = 0.21 for IgM, respectively). Within the
       ocrelizumab cohort, analysis based on age demonstrated no
       significant differences in risk for serious infection (55-60, OR
       1.11 [95% CI, 0.74-1.65]; >60, OR 1.38 [95% CI, 0.91-2.09]).
       Conclusion:
       These findings pertaining to risk of serious infection are
       consistent with those reported in the clinical trials and
       extension studies, and other observational real-world cohorts.
       The results provide the magnitude of this risk in comparison to
       platform treatment and may facilitate shared decision making
       between patients and providers to select disease modifying
       therapy.
       *****************************************************